FMP
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
NYSE
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
36.26 USD
0.92 (2.54%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Vladimir Coric M.D.
sector
Healthcare
industry
Biotechnology
exchange
NYSE
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amy...
CIK
0001689813
ISIN
VGG1110E1079
CUSIP
G11196105
Address
215 Church Street
Phone
203 404 0410
Country
US
Employee
239
IPO Date
Sep 23, 2022
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
BHVN Financial Summary
CIK
0001689813
Exchange
NYSE
Industry
Biotechnology
Sector
Healthcare
CUSIP
G11196105
ISIN
VGG1110E1079
Country
US
Price
36.26
Beta
4.12
Volume Avg.
1.05M
Market Cap
3.67B
Shares
-
52-Week
26.8-62.21
DCF
3.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.87
P/B
-
Website
https://www.biohavenpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BHVN News
It looks like there's no news available.
